Training guide for trainers on Active Tuberculosis Drug Safety Monitoring and Management (aDSM)

Active tuberculosis (TB) drug safety monitoring and management (aDSM) is a key component for the use of new TB drugs such as bedaquiline and delamanid approved by the Food and Drugs Agency of the United States in 2012. Additionally, aDSM also includes the use of repurposed drugs such as linezolid and clofazimine introduced in drug-resistant TB (DR-TB) management. Despite widespread use of these drugs by some National Tuberculosis Programmes (NTPs) among the West and Central African Regional Networks for TB control (WARN/CARN-TB), scaling up of aDSM remains suboptimal. In 2021, an assessment conducted across the networks showed that only 25.9% (7/27) NTPs had developed national guidelines for aDSM1. To overcome this challenge, standardized tools, regular training, and supervision of health care workers (HCWs) and their managers are crucial to build capacity towards optimising aDSM practices and reporting.

This training guide intends to serve as a resource document in organising the training targeted at specific audiences (Health Care Workers (HCWs), NTP managers and pharmacovigilance managerial staff). It further provides an orientation for the trainer on aspects to cover through interactives sessions to maximise the delivery of key information. Trainers will usually be country focal points with experience in aDSM or pharmacists.

Download: https://tdr.who.int/docs/librariesprovider10/adsm/adsm-training-guide.pdf?sfvrsn=82f0f450_4